...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Technology Management: The Journal of the Technology Management of Technology, Engineering Management, Technology Policy and Strategy >Innovation management of Japanese pharmaceutical companies: the case of an antibiotic developed by Takeda
【24h】

Innovation management of Japanese pharmaceutical companies: the case of an antibiotic developed by Takeda

机译：日本制药公司的创新管理：武田开发的抗生素案例

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It is often argued that the Japanese pharmaceutical industry lacks international competitiveness partly because of its weakness in innovation - most new drugs developed by Japanese companies are imitative and lack appeal in overseas markets. To address this problem, I suggest a well-defined typology of drug innovation. I found in my previous studies that the dominant type of innovation among Japanese companies has been the modification-based innovation, which indeed appears to be imitative. Although modification-based innovation is not necessarily easy it may bring in significant revenue. It is also found that institutional and organisational conditions of the Japanese market until recently were in favour of modification-based innovation. Therefore, it can be argued that innovation management of Japanese pharmaceutical companies in the past was not inappropriate. Recently, the situation is changing and some Japanese companies are seeking more radical types of innovation. But we should not underestimate the strategic value of modification-based innovation.
机译：经常有人争辩说，日本制药业缺乏国际竞争力，部分原因是其创新能力很弱-日本公司开发的大多数新药都是模仿品，在海外市场缺乏吸引力。为了解决这个问题，我建议对药物创新进行明确的分类。我在以前的研究中发现，日本公司中创新的主要类型是基于修改的创新，这确实是模仿的。尽管基于修改的创新不一定很容易，但它可能会带来可观的收入。还发现直到最近，日本市场的体制和组织条件都支持基于修改的创新。因此，可以说过去日本制药公司的创新管理是不适当的。最近，情况正在发生变化，一些日本公司正在寻求更激进的创新类型。但是，我们不应低估基于修改的创新的战略价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号